Examkin

Question

Difficulty: Very hardPulmonary and Critical Care

A 2626-year-old man is evaluated in the emergency department for severe shortness of breath. He has a history of poorly controlled persistent asthma. Over the past two days, he has been using his albuterol inhaler every hour with minimal relief. On initial presentation, he was in severe respiratory distress with a respiratory rate of 34/min34/\text{min}, prominent accessory muscle use, and minimal air entry bilaterally. He was treated aggressively with supplemental oxygen, intravenous methylprednisolone, intravenous magnesium sulfate, and continuous nebulized albuterol.

Two hours later, the patient reports feeling significantly better and is breathing more comfortably. His temperature is 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure is 122/76 mm Hg122/76\text{ mm Hg}, pulse is 112/min112/\text{min}, and respiratory rate is 20/min20/\text{min}. Pulse oximetry is 96%96\% on a 40%40\% Venturi mask. Physical examination shows no accessory muscle use, no jugular venous distention, and pulmonary auscultation reveals good bilateral air entry with mild end-expiratory wheezing.

Arterial blood gas and serum chemistry results are as follows:

ParameterValue
pH7.307.30
PaCO2_233 mm Hg33\text{ mm Hg}
PaO2_288 mm Hg88\text{ mm Hg}
Sodium139 mEq/L139\text{ mEq/L}
Potassium3.6 mEq/L3.6\text{ mEq/L}
Chloride100 mEq/L100\text{ mEq/L}
Bicarbonate16 mEq/L16\text{ mEq/L}
Lactic acid5.1 mmol/L5.1\text{ mmol/L}

Which of the following is the most appropriate next step in management?

  1. Transition to intermittent albuterol nebulization and observeAnswer
  2. B
    Perform endotracheal intubation and mechanical ventilation
  3. C
    Administer intravenous sodium bicarbonate
  4. D
    Administer intravenous furosemide
  5. E
    Administer intravenous piperacillin-tazobactam

Answer

The correct management is to transition to intermittent albuterol nebulization and observe.
The correct action is to transition to intermittent albuterol nebulization and observe. This patient presented with a severe asthma exacerbation and was treated with continuous nebulized albuterol. He now exhibits a high anion gap metabolic acidosis (AG=139−(100+16)=23AG = 139 - (100 + 16) = 23) driven by an elevated lactate (5.1 mmol/L5.1\text{ mmol/L}). Albuterol is a beta-2 adrenergic agonist that can cause a Type B lactic acidosis (without tissue hypoxia) by stimulating skeletal muscle glycolysis and lipolysis faster than pyruvate can be utilized, leading to lactate accumulation. This is a common, benign phenomenon that resolves as the beta-agonist is spaced out. Importantly, his arterial blood gas must be interpreted in context. Using Winter's formula (PaCO2=1.5×16+8=32±2PaCO_2 = 1.5 \times 16 + 8 = 32 \pm 2), we see that his PaCO2PaCO_2 of 33 mm Hg33\text{ mm Hg} is perfect respiratory compensation for his metabolic acidosis. Because he is clinically improving (decreased respiratory rate, better air movement, subjective relief), this PaCO2PaCO_2 indicates appropriate physiological compensation, not impending respiratory failure.

Step-by-Step Solution

1
Analyze the patient's basic metabolic panel to determine the primary acid-base disorder.
The anion gap is calculated as Sodium - (Chloride + Bicarbonate) = 139 - (100 + 16) = 23. This indicates a primary high anion gap metabolic acidosis.
Identifying the primary disorder is the first step in acid-base interpretation, directing the search for the underlying etiology (in this case, lactic acidosis from albuterol).
2
Apply Winter's formula to determine if the measured PaCO2 represents appropriate respiratory compensation or a secondary respiratory disorder.
Expected PaCO2 = (1.5 * HCO3) + 8 = (1.5 * 16) + 8 = 24 + 8 = 32 \pm 2 mm Hg. The patient's actual PaCO2 is 33 mm Hg.
Because the actual PaCO2 exactly matches the expected PaCO2, the patient has a pure high anion gap metabolic acidosis with appropriate respiratory compensation. There is no concurrent respiratory acidosis.
3
Correlate the objective acid-base findings with the clinical trajectory.
The patient's work of breathing has decreased, air entry has improved, and he feels better. The lactic acidosis is Type B, driven by systemic beta-2 agonist (albuterol) therapy which increases glycolysis and lactate production.
Understanding the clinical context prevents the misinterpretation of the 'normalizing' PaCO2 (33 mm Hg) as a sign of respiratory muscle fatigue.
4
Determine the therapeutic intervention based on the clinical resolution.
Because the asthma exacerbation is resolving and the lactic acidosis is an expected, benign side effect of the treatment, the correct step is to observe and begin spacing out the albuterol.
Unnecessary interventions like intubation or bicarbonate administration would be harmful in a patient who is actively improving.

Key Concept

Patients receiving high-dose beta-2 agonists for severe asthma frequently develop a benign, self-limiting Type B lactic acidosis; expected respiratory compensation (lowered PaCO2) should be calculated using Winter's formula to distinguish this from impending respiratory failure.

Alternative Method

Whenever evaluating a blood gas in an asthmatic patient, correlate the PaCO2 directly with the clinical work of breathing. If the patient is speaking in full sentences, has a respiratory rate of 20, and air entry is good, a PaCO2 of 35 is highly unlikely to represent muscle fatigue and is almost certainly compensation for a metabolic process.
Estimated Time:2m 30s
Rate this question

Topics

Pulmonary and Critical Care

More questions from this topic